Lornoxicam is indicated in:

• Short-term relief of acute mild to moderate pain
• Symptomatic relief of pain and inflammation in osteoarthritis
• Symptomatic relief of pain and inflammation in rheumatoid arthritis

Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) and antirheumatic drug of the oxicam class. It is intended for short-term treatment of acute mild to moderate pain and symptoms of rheumatoid arthritis and osteoarthritis such as pain and inflammation of joints. Lornoxicam's mode of action is mainly related to the inhibition of prostaglandin synthesis (inhibition of the cyclooxygenase enzyme), leading to desensitization of peripheral nociceptors and consequently inhibition of inflammation.

Acute Pain: 8-16 mg Lomoxicam daily divided into 2 or 3 doses. Maximum recommended daily dose is 16 mg.

Osteoarthritis and Rheumatoid arthritis: Initial recommended dose is 12 mg Lomoxicam daily divided into 2 or 3 doses. Maintenance dose should not exceed 16 mg Lomoxicam daily.

Use in Children & Adolescents: Lomoxicam is not recommended for use in children and adolescents below age 18 due to lack of data on safety and efficacy.

Elderly: No special dosage modification is required for elderly patients above age 65 but Lomoxicam should be administered with precaution as gastrointestinal adverse effects are less well tolerated in this group.

Renal Impairment: For patients with mild to moderate renal impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses. 

Hepatic impairment: For patients with moderate hepatic impairment, the maximum recommended daily dose is 12 mg divided in 2 or 3 doses. Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.

Concomitant administration of Lornoxicam with vitamin K antagonists like warfarin increases the risk of bleeding. Combination with Cyclosporin can lead to reduced kidney function and to acute kidney injury in rare cases. Lornoxicam can also increase the adverse effects of lithium, methotrexate, digoxin, and its derivatives. The effect of diuretics, ACE inhibitors, and angiotensin II receptor antagonists can be reduced in patients with heart failure.

Hypersensitivity to Lornoxicam or to any of the excipients, peptic ulcer, severe hepatic impairment, severe renal impairment (serum creatinine > 700 pmol/l), thrombocytopenia, and the third trimester of pregnancy.

The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation, or GI bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, hematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported following administration of NSAIDs.

Lornoxicam is contraindicated in the third trimester of pregnancy and should not be used during the first and second trimesters or during delivery, as no clinical data on exposed pregnancies are available. There are no data on the excretion of Lornoxicam in human breast milk. Lornoxicam is excreted in the milk of lactating rats in relatively high concentrations. Therefore, Lornoxicam should not be used in breastfeeding women.

Lornoxicam should be taken carefully when someone has impaired kidney function, a history of high blood pressure or heart failure, suffers from ulcerative colitis or Crohn's disease, has a history of bleeding tendency, has a history of asthma, suffers from SLE (Systemic Lupus Erythematosus) – a rare immunological disease – or is a woman taking treatment for infertility.

At this time, there is no experience of overdose to permit definition of the consequences of an overdose or to suggest specific management. However, it can be expected that after an overdose with Lornoxicam, the following symptoms may be seen: nausea, vomiting, cerebral symptoms (dizziness, disturbances in vision). In the case of a real or suspected overdose, the medicinal product should be withdrawn. Due to its short half-life, Lornoxicam is rapidly excreted. Lornoxicam is not dialyzable. No specific antidote is known to date. The usual emergency measures including gastric lavage should be considered.

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Keep out of the reach of children. Store below 30°C. Protect from light and moisture. Keep all medicines out of the reach of children.